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Abstract
Background: Pulmonary fibrosis has high rates of mortality and morbidity; however, no effective pharmacological
therapy has been established. C-type natriuretic peptide (CNP), a member of the natriuretic peptide family, selectively
binds to the transmembrane guanylyl cyclase (GC)-B receptor and exerts anti-inflammatory and anti-fibrotic effects in
various organs through vascular endothelial cells and fibroblasts that have a cell-surface GC-B receptor. Given the
pathophysiological importance of fibroblast activation in pulmonary fibrosis, we hypothesized that the anti-fibrotic and
anti-inflammatory effects of exogenous CNP against bleomycin (BLM)-induced pulmonary fibrosis were exerted in part
by the effect of CNP on pulmonary fibroblasts.
Methods: C57BL/6 mice were divided into two groups, CNP-treated (2.5 μg/kg/min) and vehicle, to evaluate
BLM-induced (1 mg/kg) pulmonary fibrosis and inflammation. A periostin-CNP transgenic mouse model exhibiting CNP
overexpression in fibroblasts was generated and examined for the anti-inflammatory and anti-fibrotic effects of CNP via
fibroblasts in vivo. Additionally, we assessed CNP attenuation of TGF-β-induced differentiation into myofibroblasts by
using immortalized human lung fibroblasts stably expressing GC-B receptors. Furthermore, to investigate whether CNP
acts on human lung fibroblasts in a clinical setting, we obtained primary-cultured fibroblasts from surgically resected
lungs of patients with lung cancer and analyzed levels of GC-B mRNA transcription.
Results: CNP reduced mRNA levels of the profibrotic cytokines interleukin (IL)-1β and IL-6, as well as collagen deposition
and the fibrotic area in lungs of mice with bleomycin-induced pulmonary fibrosis. Furthermore, similar CNP effects were
observed in transgenic mice exhibiting fibroblast-specific CNP overexpression. In cultured-lung fibroblasts, CNP treatment
attenuated TGF-β–induced phosphorylation of Smad2 and increased mRNA and protein expression of α-smooth muscle
actin and SM22α, indicating that CNP suppresses fibroblast differentiation into myofibroblasts. Furthermore, human lung
fibroblasts from patients with or without interstitial lung disease substantially expressed GC-B receptor mRNA.
Conclusions: These data suggest that CNP ameliorates bleomycin-induced pulmonary fibrosis by suppressing TGF-β
signaling and myofibroblastic differentiation in lung fibroblasts. Therefore, we propose consideration of CNP for clinical
application to pulmonary fibrosis treatment.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic disease
characterized by progressive scarring of the lung paren-
chyma [1]. Recent guidelines for IPF show that no effect-
ive pharmacological therapy has been established and
that the 5-year survival rate of IPF is less than 50 % [1].
More recently, pirfenidone and nintedanib were ap-
proved for the treatment of IPF due to evidence of their
efficacy in slowing functional decline and disease pro-
gression [2]. Although the pathologic processes that
cause disease progression are not fully understood, IPF
is characterized by a microscopic pattern of usual inter-
stitial pneumonia, which includes excessive collagen de-
position, honeycombing, and the presence of fibroblastic
foci [3]. Fibroblasts, which can be activated to differenti-
ate into highly secretory and contractile smooth muscle-
like cells termed myofibroblasts, are mesenchymal cells
that serve a critical role in both normal and fibrotic re-
pair processes [4]. Fibroblastic foci are areas of myofi-
broblast proliferation thought to be the main site of
abnormal collagen deposition [5]. Transforming growth
factor (TGF)-β is a key mediator of fibrosis in many tis-
sues including lung. In pulmonary fibrosis, TGF-β stim-
ulates fibroblast to myofibroblast transformation and
promotes collagen deposition of fibroblasts [6–8].
Thus, the lung fibroblasts and myofibroblasts within fi-
broblastic foci represent an attractive target for the
treatment of IPF [7].
We originally isolated C-type natriuretic peptide (CNP)
from porcine brain as the third member of the natriuretic
peptide family [9], the other members being atrial and
brain natriuretic peptide (ANP and BNP, respectively).
CNP selectively binds to the transmembrane guanylyl cy-
clase (GC)-B receptor and subsequently leads to a large in-
crease in intracellular cyclic guanosine monophosphate
(cGMP) [10]. CNP is expressed in a wide variety of tissues,
such as vascular endothelium, heart, bone, and adrenal and
reproductive glands [11–15]. CNP plays a role in the local
regulation of vascular tone and remodeling, and has been
shown to have mainly cardioprotective effects, such as an
anti-inflammatory effect, in a rat model of myocarditis [16]
and anti-hypertrophic and anti-fibrotic effects in a rat
model of myocardial infarction [17]. Recently, CNP was
shown to have protective effects against inflammatory and
fibrotic reactions in articular cartilage [18, 19], kidney [20,
21], and skin [22]. Murakami et al. [23] reported that CNP
modulated the BLM-induced inflammatory reaction by re-
ducing the production of inflammatory cell-attracting che-
mokines, but the precise mechanisms were unclear. We
recently revealed that exogenous CNP attenuates lipopoly-
saccharide (LPS)-induced acute lung injury in mice [24].
CNP is synthesized by cardiac fibroblasts as well as vascu-
lar endothelial cells in neonatal rats, and CNP plays a role
as an autocrine regulator against excessive cardiac fibrosis
and secretion of inflammatory cytokines [25, 26]. Thus, fi-
broblasts, which exist in various organs and are involved in
fibrosis, are likely target cells of CNP.
Bleomycin (BLM)-administered mice are widely used
as a model of IPF [27]. The administration of BLM
causes epithelial injury, followed by neutrophil-dominant
and lymphocyte-dominant inflammation that leads to
fibrosis [28]. In the inflammatory phase, the expression
levels of various chemokines, cytokines, and growth fac-
tors are elevated, and these mediators exert their profi-
brotic activities through the activation and proliferation
of fibroblasts [28]. Considering the pathophysiological
importance of fibroblast activation in pulmonary fibrosis
[4, 28, 29] and the above-mentioned reports about CNP
and cardiac fibroblasts [25, 26], we hypothesized that the
anti-fibrotic and anti-inflammatory effects of exogenous
CNP against BLM-induced pulmonary fibrosis were
exerted at least in part by the effect of CNP on pulmon-
ary fibroblasts.
Here we showed that CNP attenuated the inflamma-
tory reaction and fibrotic changes induced by BLM ad-
ministration in murine lung, and that BLM-induced
pulmonary inflammation and fibrosis were attenuated in
transgenic mice whose fibroblasts overexpressed CNP.
Additionally, we demonstrated the suppressive effect of
CNP in vitro on the activation of human lung fibroblasts
by TGF-β. These results suggest that the target of the
anti-fibrotic effect of CNP is lung fibroblasts. Finally, we
demonstrated that the mRNA of GC-B was expressed in
primary-cultured human lung fibroblasts from patients
with or without interstitial lung disease (ILD). These in-
sights suggest the possibility of CNP as a new thera-
peutic agent for patients with ILD including IPF.
Methods
Animal studies
C57BL/6N mice (male, 6 weeks old, weighing 18–20 g
each) were purchased from Japan SLC (Shizuoka, Japan).
Animals were maintained at a controlled temperature of
24 °C ± 1 °C with a 12:12 h light–dark cycle (light cycle,
07:00–19:00), and were fed a standard diet. Water was
freely available. All experimental protocols described
herein were approved by the Animal Care Ethics Com-
mittee of the National Cerebral and Cardiovascular Cen-
ter Research Institute, Japan.
Generation of periostin-CNP transgenic mice
The periostin–CNP transgenic construct, which drives
CNP expression under the control of the periostin pro-
moter, was generated by using the Red/ET Counter Selec-
tion bacterial artificial chromosome (BAC) modification
Kit (Gene Bridges, Heidelberg, Germany). A human BAC
clone RP11-46 M10 containing the CNP gene and a
mouse BAC clone RP23-144B14 containing the periostin
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gene (Thermo Fisher Scientific/Invitrogen, MA, USA)
were used to construct the transgene [30]. The periostin-
CNP transgenic construct was purified and microinjected
into the pronucleus of C57BL/6 J mouse embryos by use
of standard techniques. Transgenic F1 mice were identi-
fied by Southern blot analysis of tail DNA, and were then
mated with C57BL/6 J mice to produce a large number of
periostin-CNP transgenic mice. The probe for the South-
ern blot analysis was prepared by polymerase chain reaction
(PCR) with the following primers: intron forward (5′-G
GCTGTCTCCTCCGAGATG-3′), and SV40 reverse (5′-T
GAGTTTGGACAAACCACAACTAGA-3′). The hetero-
zygosity of the transgenic mice was maintained.
Analysis of transgene expression
Total RNA was prepared from mouse tissues as follows.
PCR amplification was performed with AmpliTaq Gold
polymerase (Life Technologies, Inc.) according to the
manufacturer’s instructions. To distinguish transgene ex-
pression from endogenous CNP expression, the human
CNP exon sequence and the untranslated sequence of
the transgene were used as the forward primer and re-
verse primer, respectively (forward: 5′-AAGAAGGGCT
TGTCCAAGGG-3′; reverse: 5′-GTTTCAGGTTCAGG
GGGAGG-3′). Internal control RT-PCR was performed
with the 36B4 gene.
Chemicals and reagents
BLM, purchased from Nippon Kayaku Co. (Tokyo,
Japan), was dissolved in normal saline and adjusted to
the appropriate concentrations as described below. CNP,
purchased from Peptide Institute, Inc. (Osaka, Japan),
was dissolved in 5 % w/v glucose solution at a concen-
tration of 20 mg/mL.
BLM administration and CNP treatment
BLM (1 mg/kg) in 80 μl of saline was administered via
oropharyngeal aspiration as previously described [31].
CNP (2.5 μg/kg/min) or vehicle was subcutaneously (not
intravenously) infused by using an osmotic mini-pump
(Alzet Model 1003D, Duret Corporation, Cupertino, CA,
USA) and the pumps were implanted 24 h before BLM
administration as previously described [24]; the infusion
continued until the mice were euthanized. This proto-
col resulted in the creation of three groups: normal
control mice, BLM-administered mice treated with
CNP, and BLM-administered mice treated with vehicle
(n = 18 in each group).
Bleomycin administration
The mice were anesthetized with 3 % isoflurane delivered
in a box, and BLM (1 mg/kg) in 80 μL of saline or vehicle
alone was administered via oropharyngeal aspiration with
a micropipette (day 0). Oropharyngeal aspiration was
performed as described by de Vooght et al. [31] Mice were
fixed on a surgery board, the tongue was pulled out with
the use of forceps, and the liquid was placed onto the dis-
tal part of the oropharyngeal airway while the nose was
gently closed. Mice were killed on day 14. A subgroup of
the mice was assessed by measuring cell counts in bron-
choalveolar lavage (BAL) fluid as described below, while
the remainder were euthanized for histological, gene ex-
pression, and hydroxyproline analysis of the lung. The left
lung was fixed by intratracheal instillation of 4 % parafor-
maldehyde for 24 h and subsequently embedded in paraf-
fin. Paraffin sections were stained with hematoxylin-eosin
and Masson trichrome.
BAL fluid analysis
BAL fluid was assessed as previously described [32, 33].
In an open-chest procedure, mouse trachea was cannu-
lated (20-gauge intravenous catheter) and 1 mL of PBS
was infused intratracheally and withdrawn. This lavage
technique was repeated two additional times with the
same 1.0 mL solution. BAL fluids were centrifuged at
300 × g for 10 min at 4 °C. The cell pellet was suspended
in 0.5 mL of PBS, and slides were prepared by cytocentri-
fugation (Cytospin 4, Thermo Shandon, Pittsburgh, PA,
USA) and stained with Diff-Quick (Dade Behring,
Dudingen, Switzerland). Cell counts of total cells, mac-
rophages, and neutrophils in the BAL fluid were deter-
mined by using morphological criteria under a light
microscope; ≥1000 cells/slide were evaluated.
Quantitative evaluation of lung fibrosis
Lung sections were stained with Masson trichrome,
and then each slide was scanned completely in a zigzag
fashion and the percentage of fibrotic area in the whole
lung field was assessed. Brightfield images of Masson
trichrome-stained slides were made on an FSX100 sys-
tem (Olympus, Tokyo, Japan) and the fibrotic area
expressed as a percentage of the whole lung field was
analyzed by using CellSens Dimension software version
1.6 (Olympus).
Hydroxyproline assay
Total lung collagen was determined by analysis of hy-
droxyproline on day 14 after bleomycin infusion as
previously described [34]. In brief, the left lung was ho-
mogenized in 6 N hydrochloric acid and hydrolyzed at
110 °C overnight. Citrate/acetate buffer (pH 6.5) and
chloramine T solution were added at room temperature
for 20 min. The mixture was then incubated with Ehrlich’s
solution at 65 °C for 20 min. After the samples were
cooled to room temperature, the absorbance of each sam-
ple at 550 nm was measured. Hydroxyproline content was
calculated from a standard curve of L-hydroxyproline
(Wako Pure Chemical Industries, Ltd., Osaka, Japan).
Kimura et al. Respiratory Research  (2016) 17:19 Page 3 of 17
Gene expression analysis
Total RNA from lung and other tissues was homoge-
nized in guanidium-phenol-chloroform and isolated by
using an RNeasy mini kit (Qiagen, Hilden, Germany).
Total RNA from cells in vitro was isolated by using a
QIAshredder (Qiagen) and an RNeasy mini kit. The
RNA was then reverse-transcribed into cDNA by using a
SuperScript II Reverse Transcriptase kit (Invitrogen,
Carlsbad, CA, USA) or a QuantiTect Reverse Transcrip-
tion kit (Qiagen). Quantitative PCR assays were con-
ducted in a 96-well plate with the use of SYBR Premix
Ex Taq (Takara, Siga, Japan) and a Light Cycler 480 Sys-
tem II (Roche Applied Science, Indianapolis, IN, USA).
Sequences of the primers were listed in Table 1. The
PCR settings were as follows: initial denaturation for 30s
at 95 °C followed by 38 cycles of 5 s at 95 °C, 20 s at
57 °C (IL-6), or 5 s at 95 °C, 10 s at 56 °C, 15 s at 72 °C
(IL-1β), or 5 s at 95 °C, 20 s at 60 °C (bFGF, TGF-β, and
36B4), or 5 s at 95 °C, 20 s at 58 °C (collagen 1A,
TIMP1, and SM22α), or 5 s at 95 °C, 20 s at 59 °C (α-
SMA and GC-B). Melting curve analysis was conducted
with the temperature increasing from 72 °C to 98 °C.
Quantification of gene expression was calculated relative
to the housekeeping gene 36B4.
Western blot analysis
Cultured cells were lysed in NP-40 buffer (1 % Nonidet P-
40, 20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 5 mM
EDTA) supplemented with protease and phosphatase in-
hibitor cocktails (Nacalai Tesque, Inc., Kyoto, Japan). The
sample was centrifuged at 300 × g at 4 °C for 15 min, and
the supernatant was collected. The concentration of total
protein was determined by using the Pierce 660 nm Pro-
tein Assay Reagent (Thermo Fisher Scientific, Waltham,
MA, USA). The proteins were separated by 4 to 15 % SDS-
PAGE (Bio-Rad, Hercules, CA, USA) and transferred to a
polyvinylidene fluoride membrane (Millipore, Billerica,
MA, USA). The membrane was incubated in polyvinyli-
dene blocking reagent (Toyobo, Tokyo, Japan) at room
temperature for 30 min, and then incubated at 4 °C over-
night with the appropriate primary antibody diluted in Can
Get Signal Solution 1 (Toyobo). The primary antibody was
detected by a horseradish peroxidase-conjugated secondary
antibody diluted in Tris-buffered saline (pH 7.4) containing
0.1 % Tween 20 and visualized with Luminata Forte
Western HRP substrate (Millipore, Billerica, MA, USA).
An image of the membrane was obtained by using a LAS-
4000 mini luminescent image analyzer (Fujifilm, Tokyo,
Japan), and band intensities were quantitated by using
Multi Gauge software (version 3.11, Fujifilm). Protein levels
were normalized to the level of GAPDH and expressed as
the ratio of the level in control mice. The primary anti-
bodies used for the analysis were as follows: anti-alpha
smooth muscle actin (α-SMA) antibody (ab5694, Abcam,
Cambridge, UK), anti-SM22α antibody (ab14106, Abcam),
anti-Fibronectin antibody (ab2413, Abcam), GAPDH
Rabbit mAb (#3683, Cell Signaling Technology, Beverly,
MA, USA), Phospho-Smad2 antibody (#3101, Cell Signal-
ing Technology), and Smad2/3 antibody (#3102, Cell Sig-
naling Technology).
Specimens of human lung tissue
From the lung cancer resection specimens of 8 lung can-
cer patients, we harvested grossly normal-appearing lung
tissues that were ≥5 cm away from the tumor. Of these
8 patients, 5 had ILD including IPF.
Isolation and primary culture of lung fibroblasts
The tissues were placed in DMEM supplemented with an-
tibiotics for immediate transportation on ice to the labora-
tory. Tissues were minced into small pieces and digested
for 1 h at 37 °C in HBSS (Life Technologies, Carlbad, CA,
USA) containing 2 mg/mL collagenase A (10103586001;
Roche Diagnostics, Mannheim, Germany). The cell sus-
pension was filtered with a stainless steel wire mesh (hole
size, 500 μm) and then a 100-μm cell strainer (BD Biosci-
ences, San Jose, CA, USA). Cells in DMEM containing
10 % FCS were plated on 100-mm tissue-culture plates as
Table 1 Sequence of primers used in the study
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previously described [35]. The primary cells used in the
experiments were not cultured beyond 3 passages, ex-
cept fibroblasts used in the in vitro studies described
below which were obtained from one of the patients
without ILD.
Immortalization of human lung fibroblasts by using
lentivirus that expressed human telomerase
To facilitate the in vitro studies of human normal lung
fibroblasts (LFs), primary cultured LFs were immortal-
ized with human telomerase (hTERT)-expressing lenti-
virus as previously described [36]. An early passage
culture of LFs was infected with hTERT-expressing
lentivirus (kindly provided from KAN Research Insti-
tute Inc., Kobe, Japan). After infection, cells were se-
lected with neomycin. The resultant cell line is referred
to as LFhTERT.
Plasmids, transfection, and infection
The plasmid used for preparing retrovirus vector ex-
pressing GC-B-Flag (pCX4 puro GC-B-FLAG) was con-
structed by PCR amplification of the human GC-B gene
(obtained from Promega, Madison, WI, USA) with the
forward primer (GCB NotI F2), 5′- AAAGCGGCCGCA
CCATGGCGCTGCCATCACTTCTGCTGTTG-3′, and
the reverse primer (GCB Flag R NotI), 5′- TTTGCGG
CCGCTCACTTGTCATCGTCGTCCTTGTAGTCCAG
GAGTCCAGGAGGTCCTTTCCGCTCTC −3′, and then
introducing the amplified GC-B-Flag fragment into the
NotI site of pCX4 puro [34]. The vector was transfected
into BOSC 23 cells with pE-eco and pGp (Takara Bio,
Shiga, Japan) by using FuGENE6 (Promega). After trans-
fection, culture supernatants were collected, filtered, and
used for infection. Retroviral infection of LFhTERT was per-
formed by using the retrovirus expressing GC-B-FLAG
and Ecotropic Receptor Booster (Takara Bio) according to
the manufacturer’s directions. After infection, cells were
selected with puromycin. The resultant cell line is referred
to as LFhTERT/GC-B.
Assay for cGMP of cells
Cells were serum-starved for 12 h before the cGMP assay
and then incubated at 37 °C with 5 % CO2 in DMEM con-
taining 0.5 mM IBMX (3-isobutyl-1-methylxanthine)
(Wako) and 1 × 10−9 to 1 × 10−6 M CNP or vehicle (5 %
glucose) for 15 min. The reaction was terminated by
addition of 400 μL of 70 % ethanol containing 0.1 M
hydrochloric acid, and the cGMP concentrations were
measured with a cyclic GMP radio immunoassay kit
(Yamasa, Tokyo, Japan).
Extracellular matrix–remodelling assay
Fibroblast contractility was assessed by measuring changes
in the surface area of type I collagen gels mediated by
fibroblasts as previously described [37]. Serum-free
DMEM was used in the assay to exclude the modulation
of growth factors contained in serum [37]. The gels com-
prised type I collagen (Gibco, A10483-01; 0.75 mg/mL)
and the cell suspension (5 × 105 cells/mL) in HEPES-
buffered DMEM (pH 7.4). Once the gels were set, cells
were maintained in serum-free DMEM. TGF-β was added
to the medium at a final concentration of 1 ng/mL. CNP
was added to the medium at a final concentration of 1 μM
every 24 h. After the fibroblasts were cultured in the gels
for 3 days, the gels were released from the plate and the
diameter of the gel was measured by using an image scan-
ner connected to a computer running the public domain
NIH image analyzing software (ImageJ version 1.48; avail-
able from http://imagej.nih.gov/ij). The percentage of con-
traction was calculated by using the formula 100 × (well
diameter – gel diameter)/well diameter.
Ethics
Written informed consent was obtained from all patients
in this study, in accordance with ethics committee re-
quirements from the institutes and the Declaration of
Helsinki. This study protocol was approved by Institu-
tional Review Board (IRB) of Osaka University Graduate
School of Medicine.
Statistical analysis
Data were analyzed with StatView for Windows (SAS In-
stitute Inc., Cary, NC, USA), and are expressed as
means ± SEM. Between-group comparisons were per-
formed by using the Mann–Whitney U test or the un-
paired Student’s t-test. For multiple-group comparisons,
one-way ANOVA, followed by the post-hoc Fisher’s least
significant difference test, was used. P < 0.05 was consid-
ered to be significant.
Results
CNP ameliorated BLM-induced lung fibrosis and
inflammation in mice
First, we examined the in vivo anti-inflammatory and anti-
fibrotic effects of CNP by using a BLM-induced lung
fibrosis model in C57BL/6 mice. The histological findings
confirmed that BLM administration induced lung paren-
chymal fibrotic lesions (Fig. 1a, b, d, e). Continuous sub-
cutaneous infusion of CNP attenuated the BLM-induced
fibrotic changes (Fig. 1a–f ). Quantitative histological ana-
lysis showed that BLM-induced fibrotic lesions were sig-
nificantly smaller in mice treated with CNP than in those
treated with vehicle alone (Fig. 1g). CNP significantly re-
duced the amount of hydroxyproline, an indicator of the
amount of collagen, in BLM-administered lung (Fig. 1h).
CNP treatment tended to improve body weight loss by
BLM administration (Fig. 1i). BLM administration signifi-
cantly augmented the number of inflammatory cells (total
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Fig. 1 (See legend on next page.)
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cells, macrophages, or neutrophils) in bronchoalveolar
lavage (BAL) fluid (Fig. 1j–l). In BAL fluid, both total and
individual cell counts were significantly lower in CNP-
treated mice than in vehicle-treated mice. These results
indicate that CNP can attenuate the fibrotic changes and
the accumulation of inflammatory cells in BLM-induced
pulmonary fibrosis.
CNP attenuated the expression of cytokines induced by
BLM in mouse lung
To evaluate the anti-inflammatory and anti-fibrotic effects
of CNP in BLM-induced lung fibrosis, we analyzed mRNA
expression changes of pro-inflammatory cytokines (IL-1β
and IL-6), pro-fibrotic cytokines and proteins (bFGF,
TGF-β, TIMP1, and collagen 1A), and GC-B in the lungs.
The mRNA expression levels of these genes were all sig-
nificantly elevated on day 14 after BLM administration.
CNP treatment significantly reduced the mRNA expres-
sion levels of IL-1β, IL-6, and bFGF compared with those
in the vehicle control (Fig. 2a–c); the mRNA expression
levels of collagen 1A, TIMP1, and GC-B were not statisti-
cally different (Fig. 2d, e). The gene expression of TGF-β
was similar between the CNP-treated and vehicle-treated
mice (Fig. 2f). These results indicate that CNP has the po-
tential to attenuate the production of pro-inflammatory
and pro-fibrotic cytokines and the collagen accumulation
in pulmonary fibrosis.
Generation of periostin-CNP transgenic mice
To examine the anti-inflammatory and anti-fibrotic ef-
fects of CNP via fibroblasts in vivo, we generated a
periostin-CNP transgenic (Tg) mouse model in which
CNP was overexpressed (under the control of the perios-
tin promoter) (Fig. 3a, b). We confirmed the transgene
expression in various organs (aorta, heart, lung, kidney,
liver, and brain) (Fig. 3c) and primary cultured lung fi-
broblasts from a periostin-CNP Tg mouse (Fig. 3d) by
RT-PCR analysis. Expression of the transgene was ob-
served in primary cultured lung fibroblasts from the
periostin-CNP Tg mouse but not in those of its wild-
type (WT) littermate; in contrast, expression of the GC-
B gene was observed in primary cultured lung fibroblasts
from both the periostin-CNP Tg mouse and its WT lit-
termate (Fig. 3d). The concentration of CNP was signifi-
cantly higher in organs (aorta, heart, and lung) of
periostin-CNP Tg mice than those of WT littermates; in
contrast, the CNP in plasma samples of both periostin-
CNP Tg and WT mice were not detected (Fig. 3e). Body
weight and organ size were not different between
periostin-CNP Tg mice and WT littermates (Fig. 3f ).
BLM-induced pulmonary fibrosis was alleviated in
periostin-CNP Tg mice
We examined the in vivo anti-fibrotic effect of CNP via
lung fibroblasts by using periostin-CNP Tg mice in the
BLM-induced lung fibrosis model. There was no death
in this experiment. In periostin-CNP Tg mice, BLM-
induced pulmonary fibrotic change was markedly sup-
pressed when compared with that in WT littermates
(Fig. 4a–h). Quantitative histological analysis revealed
that BLM-induced fibrotic lesions were significantly
smaller in periostin-CNP Tg mice than in WT litter-
mates (Fig. 4i), suggesting that CNP exerts its anti-
fibrotic effect in the lung through fibroblasts. The lung
weight was significantly increased by BLM administra-
tion (Fig. 4j).
Expression of cytokines induced by BLM in mouse lung
was alleviated in periostin-CNP Tg mice
To evaluate the anti-inflammatory and anti-fibrotic ef-
fects of CNP against BLM-induced lung fibrosis in
periostin-CNP Tg mice, we analyzed the mRNA expres-
sion changes of IL-1β, IL-6, bFGF, TGF-β, TIMP1, and
collagen 1A. In periostin-CNP Tg mice, the gene expres-
sion levels of IL-1β, IL-6, and collagen 1A were signifi-
cantly decreased compared with those in WT littermates
(Fig. 5a, b, d). TIMP1 mRNA expression was not signifi-
cantly difference in periostin-CNP Tg mice and WT lit-
termates (Fig. 5e). Neither TGF-β nor bFGF mRNA
expression levels differed significantly between the
groups (Fig. 5c, f ). The results indicate that CNP pro-
duced anti-inflammatory and anti-fibrotic effects in the
BLM-induced pulmonary fibrosis model in periostin-
CNP Tg mice.
(See figure on previous page.)
Fig. 1 Continuous infusion of C-type natriuretic peptide (CNP) attenuated bleomycin (BLM)-induced pulmonary fibrosis in mice. BLM (1 mg/kg)
was administered intratracheally to C57BL/6 mice on day 0, and the samples were removed on day 14. CNP (2.5 μg/kg/min) or vehicle (5 % w/v
glucose solution) was subcutaneously infused throughout the experiment with the use of an osmotic mini-pump. Representative micrographs of
lung tissue stained with hematoxylin-eosin (HE; a–c) and with Masson trichrome (MT; d–f)); normal control mice (a, d), BLM-instilled mice treated
with vehicle alone (b, e) and BLM-instilled mice treated with CNP (c, f). Scale bar: 500 μm. g Fibrotic area was calculated by using image analyzing
software and expressed as a percentage of the whole lung field. Values represent means ± SEM (n = 4 mice per group). *P < 0.05. NA, not assessed
because of no fibrotic area in normal lungs. h Total collagen deposition was assessed by analyzing hydroxyproline concentrations in mouse lung
tissue. Values represent means ± SEM (n = 6 mice per group). *P < 0.05. i The body weight changes of mice after BLM administration are shown
for normal control mice (dotted line), BLM-instilled mice treated with vehicle alone (dashed line), and BLM-instilled mice treated with CNP (solid
line). Values represent means ± SEM (n = 6 mice per group). j–l The numbers of total cells (j), macrophages (k), and neutrophils (l) in bronchoalveolar
lavage (BAL) fluid on day 14 after BLM administration are shown. Values represent means ± SEM (n = 4 mice per group). *P < 0.05
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Establishment of immortalized human lung fibroblasts
stably expressing GC-B (LFhTERT/GC-B)
Our observations that CNP exerted anti-inflammatory
and anti-fibrotic effects in both the exogenous CNP-
infusion and periostin-CNP Tg experimental models,
without significant changes in TGF-β gene expression,
prompted us to hypothesize that CNP suppresses
downstream signals of TGF-β and differentiation of
lung fibroblasts. To test this, we isolated lung fibro-
blasts (LFs) from a non-tumor region of lung from a
lung cancer patient without ILD and confirmed that the
fibroblasts produced cGMP following CNP treatment
Fig. 2 Continuous infusion of CNP attenuates the induction of pro-inflammatory and pro-fibrotic cytokines in BLM-administered mice. Quantitative
RT-PCR analysis of interleukin (IL)-1β (a), IL-6 (b), basic fibroblast growth factor (bFGF) (c), collagen 1A (d), tissue inhibitor of metalloproteinase (TIMP) 1
(e), transforming growth factor (TGF)-β (f), and guanylyl cyclase (GC)-B (g) mRNA levels in lung tissues on day 14 after BLM administration was performed.
The relative mRNA expression levels of each cytokine in normal control, BLM plus vehicle-administered, or BLM plus CNP-administered mice are shown.
Values represent means ± SEM (n= 4 mice per group). *P < 0.05
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Fig. 3 Generation of the periostin-C-type natriuretic peptide transgenic mouse (periostin-CNP Tg mouse). a Schematic representation of the
periostin-CNP transgene. The transgene consisted of the periostin promoter (containing the 5′-untranslated region, shown as a gray box) linked
to the human CNP gene (exons indicated by closed boxes) and an SV40 polyadenylation sequence. The probe (855 bp) used for Southern blot
analysis is indicated by a double-headed arrow. b Southern blot analysis of EcoRV-digested mouse genomic DNA from a periostin-CNP Tg mouse
and its wild-type (WT) littermate hybridized with the probe for hCNP transgene indicated in Fig. 3a. c The expression of the transgene was examined
in aorta, heart, lung, kidney, liver, and brain by reverse transcribed–PCR. Tg, periostin-CNP transgenic mouse; WT, wild-type littermate. d The mRNA
expression levels of the transgene and GC-B receptor were examined in primary cultured lung fibroblasts from a periostin-CNP Tg mouse and its WT
littermate by PCR. A representative image of 3 independent experiments is shown. e The concentration of CNP in plasma, aorta, heart, and lung (WT,
n = 3; Tg, n = 3). *P < 0.05. ND, not detected. f Body weight and weights of lung, heart and kidney. Values represent means ± SEM (WT, n = 7; Tg, n = 5)
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in a concentration-dependent manner (Fig. 6a). It is
previously reported that the amount of GC-B receptor
in cultured cells and cell lines decreased with the num-
ber of passages [38–40]. To facilitate in vitro studies of
human LFs, LFs were immortalized and GC-B recep-
tors were stably expressed to create the LFhTERT/GC-B
cell line. We confirmed the CNP-induced dose-
dependent elevation of cGMP in the LFhTERT/GC-B
cell line (Fig. 6b).
TGF-β–induced differentiation of human lung fibroblasts
to myofibroblasts was attenuated by CNP
When stimulated with TGF-β, fibroblasts differentiate into
myofibroblasts and show increased gel contractility in an
extracellular matrix-remodeling assay [37]. Therefore we
first examined whether stimulation of LFhTERT/GC-B cells
with TGF-β also results in increased gel contractility. The
ability of LFhTERT/GC-B cells to contract collagen gel was
significantly increased by TGF-β stimulation, and this
Fig. 4 BLM-induced pulmonary fibrosis in periostin-CNP Tg mice. BLM (1 mg/kg) was administered intratracheally to periostin-CNP Tg mice and
WT littermates on day 0, and the lung tissues were removed on day 14. Representative micrographs of lung tissue stained with hematoxylin-eosin (HE;
upper panels) or Masson trichrome (MT; lower panels); WT littermates without BLM administration (a, e), periostin-CNP Tg mice without BLM administration
(b, f), WT littermates with BLM administration (c, g), and periostin-CNP Tg mice with BLM administration (d, h) are shown. Scale bar: 500 μm. i Fibrotic area
was analyzed by using image analyzing software and is expressed as a percentage of the whole lung field. Values represent means ± SEM (WT without
BLM, n= 7; Tg without BLM, n= 7; WT with BLM, n= 8; Tg with BLM, n= 9). *P< 0.05. NA, not assessed because of no fibrotic area in normal lungs. j Lung
weight. Values represent means ± SEM (WT without BLM, n= 7; Tg without BLM, n= 5; WT with BLM, n= 7; Tg with BLM, n= 5). *P< 0.05
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increase was reversed by CNP treatment (Fig. 6c). In re-
sponse to TGF-β, LFhTERT/GC-B cells upregulated the
production of α-SMA and SM22α, which was suppressed
by CNP treatment (Fig. 6d, e). The protein expression
levels of fibronectin and connective tissue growth factor
(CTFG) were also upregulated by TGF-β stimulation and
attenuated by CNP treatment (Fig. 6f). To elucidate the
mechanism by which CNP inhibits TGF-β–mediated
myofibroblast differentiation, we examined the influence
of CNP on Smad phosphorylation, which occurs immedi-
ately following TGF-β stimulation [41]. As shown in
Fig. 6g, CNP treatment suppressed TGF-β–induced
phosphorylation of Smad2. These results suggest that
CNP attenuates TGF-β–induced differentiation of fibro-
blasts into myofibroblasts via inhibition of the TGF-β/
Smad2 signaling pathway.
Human lung fibroblasts derived from patients with or
without ILD express similar levels of GC-B to each other
To investigate whether CNP acts on human lung fibro-
blasts in a clinical setting, we obtained primary-cultured
fibroblasts from the surgically resected lungs of lung can-
cer patients. Human distal parenchymal fibroblasts were
isolated from the lung tissue of patients with interstitial
Fig. 5 Changes in pulmonary inflammation and collagen deposition in periostin-CNP Tg mice after BLM administration. Quantitative RT-PCR analysis
of IL-1β (a), IL-6 (b), bFGF (c), collagen 1A (d), TIMP1 (e), and TGF-β (f) in lung tissues at 14 days after BLM administration was performed. The relative
mRNA expression levels (mean of WT littermates = 1) of each cytokine in WT littermates without BLM (n = 5), periostin-CNP Tg mice without
BLM (n = 6), WT littermates with BLM (n = 9), or periostin-CNP Tg mice with BLM (n = 6) are shown. Values represent means ± SEM. *P < 0.05
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Fig. 6 (See legend on next page.)
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lung disease (ILD; n = 5) or without interstitial lung dis-
ease (control; n = 3) (Fig. 7a, b). Demographic information
for the patients who provided fibroblasts is summarized in
Table 2. Fibroblasts used in the in vitro studies described
above were obtained from patient number 1 without ILD.
While the lung fibroblasts from ILD patients showed rela-
tively high expression of α-SMA mRNA compared with
those without ILD (Fig. 7c) as reported [7, 42], GC-B
mRNA was expressed abundantly in both groups (Fig. 7d).
These results suggest that CNP potentially affects human
lung fibroblasts equally in patients with or without ILD.
Discussion
Here, by using a bleomycin-induced lung fibrosis mouse
model, we demonstrate that CNP has an anti-fibrotic ef-
fect in lungs through pulmonary fibroblasts. We show that
BLM-induced pulmonary fibrosis is attenuated in both
CNP-treated mice and periostin-CNP Tg mice by the CTP
downregulating pro-inflammatory and pro-fibrotic cyto-
kines and inhibiting collagen deposition. We reveal that
CNP affects human lung fibroblasts in vitro and attenu-
ates their activation by TGF-β via TGF-β-Smad2 signaling.
These findings highlighted one of the mechanisms of anti-
fibrotic effect of CNP that was unclear in the previous
study [23]. In addition, we demonstrate that human lung
fibroblasts express the GC-B receptor, regardless of the
presence or absence of ILD in the patient of origin, sug-
gesting that CNP could potentially have a therapeutic ef-
fect in humans.
Anti-inflammatory and anti-fibrotic effects of CNP
have been reported in various tissues [16, 18–22]. Pre-
vious study showed that CNP is expressed in all major
cell types in the lung during development and exerts ef-
fects on the airway epithelium [43, 44]. In lungs, CNP
infusion inhibits the infiltration of inflammatory cells,
including macrophages and monocytes, neutrophils,
and lymphocytes in a monocrotaline-induced pulmon-
ary hypertension rat model [45] and an LPS-induced
acute lung injury mouse model [24]. These studies fo-
cused mainly on vascular endothelial cells as a site
where CNP functions. CNP has been reported to inhibit
the LPS-induced inflammatory reaction and expression
of adhesion molecules in human endothelial cells in
vitro [46]. Murakami et al. [23] reported that CNP
modulated the BLM-induced inflammatory reaction by
reducing the production of inflammatory cell-attracting
chemokines. In our results, the vasoprotective effect of
CNP could result partially in the attenuation of inflamma-
tory cell infiltration induced by BLM via reduction of ad-
hesion molecules. Although mRNA expressions of Col1A
and TIMP-1 were not statistically different between
vehicle-treated mice and CNP-treated mice, we speculate
that the CNP-induced tendency of decrease in these
mRNA expressions lead to the significant decrease in ac-
cumulation of hydroxyproline by reducing both produc-
tion and decomposition of collagen. Inflammation is the
initial step of fibrosis, and once fibrotic change occurs, fi-
broblasts and myofibroblasts increase in number due to
proliferation of these cells [47]. Fibroblasts and myofibro-
blasts regulate chronic persistent inflammation and are
the effector cells in the development of tissue fibrosis [4].
Since CNP has an anti-fibrotic effect in various tissues
and regulates activated cardiac fibroblasts, we focused on
the pulmonary fibroblasts as another target of CNP in the
BLM-induced pulmonary fibrosis model.
Periostin, which is mainly produced by fibroblasts, is a
recently characterized matricellular protein that binds to
matrix proteins (collagen I, fibronectin, and tenascin-C)
and interacts with several integrin molecules (i.e., αv, β1,
β3, and β5) on cell surfaces, providing signals for tissue
development and remodeling [28, 48]. Periostin is inte-
gral to wound healing, skin sclerosis, and fibrosis in
myocardial infarction [49–51]. In the lung, periostin reg-
ulates inflammation and promotes extracellular matrix
deposition in BLM-induced lung injury in mouse [28,
52], and also influences pathogenesis in human IPF [52].
(See figure on previous page.)
Fig. 6 CNP attenuated TGF-β-induced fibroblast differentiation in human lung fibroblasts. Primary cultured human lung fibroblasts (LF) from a surgically
resected specimen of a lung cancer patient (a) and its immortalized and GC-B stably expressed cell-line (LFhTERT/GC-B) (b) were treated with CNP at 10
nM to 1 μM in combination with 3-isobutyl-1-methylxanthine (0.5 mM). The cGMP concentrations in the cell lysate were measured 15 min
after CNP-treatment. Relative concentrations of cGMP (mean of control without CNP = 1) are shown. Values represent means ± SEM. c Gels
comprising type I collagen (0.75 mg/ml) and LFhTERT/GC-B cell suspension (5 × 105 cells/ml) were maintained in serum-free DMEM with or
without 1 ng/ml TGF-β. CNP was added to the medium at a final concentration of 1 μM every 24 h. After 3 days, the gels were released from
the plate and their diameter was measured. The percentage of contraction is shown. Values represent means ± SEM. *P< 0.05. Results are representative
of three independent experiments. d and e The relative mRNA expression of α-SMA (d) and SM22α (e). LFhTERT/GC-B cells were serum-starved
for approximately 24 h. The cells were then pretreated with CNP (1 μM) in DMEM + 1 % FCS for 30 min and treated with or without TGF-β
(1 ng/ml) for 24 h (for mRNA analysis) or 48 h (for protein analysis). Expression levels were normalized to that of 36B4 mRNA, and then relative
expression levels were calculated (mean of control = 1). Values represent means ± SEM. *P < 0.05. Results are representative of three independent
experiments. f Immunoblot analysis of α-smooth muscle actin (SMA), SM22α, fibronectin, connective tissue growth factor (CTGF), and glyceraldehyde
3-phosphate dehydrogenase (GAPDH). Cells were treated as in (d). Then cell lysates were prepared and subjected to immunoblot analysis. A representative
blot of three independent experiments is shown. g The LFhTERT/GC-B cells were serum-starved for approximately 24 h. The cells were then pretreated with
CNP (1 μM) in DMEM+ 1 % FCS and treated with or without TGF-β (1 ng/ml) for 30 min. Cell lysates were immunoblotted for phospho-Smad 2 (p-Smad2)
or total Smad 2 (t-Smad2). A representative blot of three independent experiments is shown with the ratio of the p-Smad2 to t-Smad2 signal intensities
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Here, we generated mice overexpressing CNP by using
the mice periostin promoter to focus on the effect of
CNP in lung fibroblasts. Because all the examined or-
gans (aorta, heart, lung, kidney, liver, and brain) contain
fibroblasts in nature and periostin is dominantly but not
specifically expressed by fibroblasts, expression of the
transgene was observed in each organ of periostin-CNP
Tg mice. We confirmed that the mRNA expression of
the transgene was observed only in the cultured lung
fibroblasts from periostin-CNP Tg mice (and not in
those from WT littermates) and that the mRNA of GC-
B receptor was expressed in both Tg and WT mice. Add-
itionally, we confirmed that the concentration of CNP in
the lung of periostin-CNP Tg mice was higher than the
concentrations found in the other organs and in WT
mice. These results demonstrate that periostin-CNP Tg
is a model for elucidation of the anti-inflammatory and
anti-fibrotic effects of CNP, which is expressed in part
Fig. 7 Human lung fibroblasts express GC-B to a similar extent with or without interstitial lung disease (ILD). Representative computed tomography
images of human lung with (a) or without (b) ILD. c The expression of α-SMA was measured by qRT-PCR analysis in RNA extracts of primary cultured
human lung fibroblasts that were obtained from surgically resected specimens of lung cancer patients with (n = 5) or without (n = 3) ILD. The α-SMA
mRNA levels were normalized to 36B4 mRNA levels, and then relative expression levels (mean of normal = 1) were calculated. The bar represents the
mean value of each group. d The mRNA expression of GC-B was examined in the primary cultured human lung fibroblasts by RT-PCR. N: negative control
(water). P: positive control
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by fibroblasts and affects fibroblasts. CBP also affects fi-
broblasts that are found in lung tissue. Our results from
studying BLM-induced lung fibrosis in these mice indi-
cate that CNP affects not only endothelial cells but also
fibroblasts and has the potential to attenuate the pro-
duction of inflammatory cytokines and collagen accu-
mulation in vivo. Because the concentration of CNP in
plasma from both periostin-CNP Tg and WT mice was
too low to be detected, the effects of CNP in this model
was thought to be autocrine or paracrine rather than
endocrine.
TGF-β, one of the most potent profibrotic cytokines, in-
duces differentiation of fibroblasts to myofibroblasts [53].
As previously reported [8, 54], TGF-β is up-regulated in
IPF, which leads to myofibroblast differentiation and en-
hanced secretion of extracellular matrix that, in turn, leads
to the development of fibrotic foci [8, 55]. However, our
data showed that CNP did not attenuate the mRNA ex-
pression of TGF-β in lungs in either the CNP administra-
tion or periostin-CNP Tg mouse model, while CNP
attenuated the fibrotic changes in BLM-injured lungs.
TGF-β is stored in extracellular matrix as a latent complex
and becomes active through contractile forces generated
by fibroblasts and myofibroblasts [56]. Fibroblasts and
myofibroblasts express a similar level of total TGF-β (i.e.,
latent plus active TGF-β) to each other [56]. Our in vitro
data showed that CNP treatment suppressed the TGF-β–
induced increase of gel contractility and expression of
myofibroblastic markers (α-SMA, SM22α, fibronectin, and
CTGF) in human lung fibroblasts. Taken together, these
findings suggest that the in vivo anti-fibrotic effect of CNP
might be exerted via lung fibroblasts by disturbing the
TGF-β–mediated transformation of lung fibroblasts to
myofibroblasts.
Activated TGF-β ligands bind to a heteromeric complex
of type I and type II receptors that transduce intracellular
signals via phosphorylation of receptor-associated Smad2
and Smad3 [42, 57]. Phosphorylation of Smad2 and
Smad3 followed by their nuclear translocation are critical
steps in TGF-β signaling [42, 57]. B-type natriuretic pep-
tide can prevent TGF-β–induced myofibroblast formation
from cardiac fibroblasts [58]. Li et al. [59] reported that
ANP/cGMP/PKG signaling intercepts the TGF-β signaling
cascade in cardiac fibroblasts. Here, we revealed that CNP
inhibited TGF-β–induced myofibroblast differentiation in
human lung fibroblasts via the inhibitory effect of CNP on
TGF-β-stimulated phosphorylation of Smad2. Considering
that the bioactivity of CNP is mainly mediated by its spe-
cific receptor GC-B [10], CNP/GC-B/cGMP signaling
may intercept the TGF-β signaling cascade in lung fibro-
blasts. Our in vitro study showed that CNP modulated at
baseline without TGF-β stimulation. We speculate that
this is because CNP suppressed not only TGF-β/Smad2
signal [40, 60]. The effect seemed to be mild at best by
PCR. However, we think that the results of PCR and west-
ern blot analysis were not inconsistent because we
assessed mRNA expression 24 h after stimulation and ac-
cumulated protein production 72 h after stimulation. Fur-
thermore, we confirmed that GC-B is expressed in the
human lung fibroblasts of patients with or without ILD.
This suggests a therapeutic potential of CNP for patients
with ILD including IPF. However, further study to clarify
the detailed mechanism of action and appropriate dose
and method of administration are warranted before clin-
ical application. We have reported the effects of ANP in
acute lung injury [61] and lung cancer metastasis [62] and
we think that both CNP and ANP have anti-inflammatory
effects in the lungs. We speculate that combined therapy
of CNP and ANP may be more effective because their
transmembrane receptors are different.
We have some limitations in this study. First, periostin
is dominantly but not specifically expressed by fibroblasts
and we should have selected the promoter which was
more specific to fibroblast. However, we had difficulty in
Table 2 Demographic information for patients who provided fibroblasts
Patient Age/Sex Histology KL-6a (U/mL) SP-Db (ng/mL) FVC (L) FEV1.0 (L) TLC (L) DLco (mL/min/mmHg)
With ILD 1 84/M Sq 613 159 2.13 1.76 3.84 6.06
2 69/M Sq 622 159 3.07 2.23 4.29 8.79
3 64/M Ad 1129 321 2.77 2.27 4.25 12.0
4 79/M Sq 599 62.4 2.85 2.14 4.36 9.75
5 77 M Sq 658 103 2.71 2.21 4.32 12.9
Without ILD 1 81/F Ad NDc NDc 1.95 1.45 3.24 9.84
2 79/F Sq NDc NDc 2.27 1.76 3.98 12.8
3 81/M Ad NDc NDc 3.17 2.18 5.39 16.3
Definition of abbreviations:
ILD interstitial lung disease, Sq squamous cell carcinoma, Ad adenocarcinoma, SP-D surfactant protein-D, FVC forced vital capacity, FEV1.0 forced expiratory volume
1.0 (sec), TLC total lung capacity, Dlco diffusing capacity of the lung carbon monoxide
aNormal range of serum KL-6 is <500U/mL
bNormal range of serum SP-D is <110 ng/mL
cThe serum levels of KL-6 and SP-D in the patients without ILD were not examined
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generating periostin-CNP Tg mice and it may be more dif-
ficult to generate CNP-Tg mice using the other promoter
more specific to fibroblast. Second, the fact that GC-B
mRNA is expressed in human lung fibroblasts does not
provide any evidence that the protein is present and that
downstream pathways are functional. Further study to dis-
close whether there is any difference in protein expression
levels and downstream pathways of GC-B between ILD
and non-ILD patients is warrant. We are performing a
study on the assessment of plasma concentrations of CNP
in humans, and then will plan the clinical trial to elucidate
the effect of CNP in humans.
Conclusions
Our results suggest that CNP exerts anti-inflammatory and
anti-fibrotic effects in a BLM-induced lung fibrosis mice
model through lung fibroblasts possibly by disturbing the
TGF-β-Smad signaling pathway, thereby attenuating the
transformation of the lung fibroblasts to myofibroblasts.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conception and Design: TK. Analysis and Interpretation: TK, JH, HH, KM.
Collecting the data: TK, JH, HH, KM, YS, MZ, HT. Drafting the manuscript for
important intellectual content: TK, TN, JH, HH, KM, YS, MI. Obtaining the
funding: TK, MM, OM, KK. All authors have approved the version of the
submitted manuscript.
Acknowledgements
We thank R. Weingerg for providing the hTERT immortalizing gene. We
thank K. Sasai and T. Akagi for providing the lentivirus vector expressing
hTERT. This work was supported in part by Grant-in-Aid for Young Scientists
B (26861135) and a grant from the Takeda Science Foundation.
Author details
1Department of Biochemistry, National Cerebral and Cardiovascular Center
Research Institute, 5-7-1, Fujishirodai, Suita-city, Osaka 565-8565, Japan.
2Department of General Thoracic Surgery, Osaka University Graduate School
of Medicine, Suita-City, Osaka, Japan. 3Department of Regenerative Medicine
and Tissue Engineering, National Cerebral and Cardiovascular Center,
Suita-City, Osaka, Japan. 4Department of General Thoracic Surgery, Kyoto
Prefectural University of Medicine, Kyoto-City, Kyoto, Japan.
Received: 28 August 2015 Accepted: 13 February 2016
References
1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official
ats/ers/jrs/alat statement: Idiopathic pulmonary fibrosis: Evidence-based
guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;
183:788–824.
2. Bonella F, Stowasser S, Wollin L. Idiopathic pulmonary fibrosis: current
treatment options and critical appraisal of nintedanib. Drug Des Devel Ther.
2015;9:6407–19.
3. Lynch 3rd JP, Saggar R, Weigt SS, Zisman DA, White ES. Usual interstitial
pneumonia. Semin Respir Crit Care Med. 2006;27:634–51.
4. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts
and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell
Biol. 2002;3:349–63.
5. Vuga LJ, Milosevic J, Pandit K, Ben-Yehudah A, Chu Y, Richards T, et al.
Cartilage oligomeric matrix protein in idiopathic pulmonary fibrosis. PLoS
One. 2013;8:e83120.
6. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al.
The integrin alpha v beta 6 binds and activates latent tgf beta 1: A
mechanism for regulating pulmonary inflammation and fibrosis. Cell.
1999;96:319–28.
7. Roach KM, Wulff H, Feghali-Bostwick C, Amrani Y, Bradding P. Increased
constitutive alphasma and smad2/3 expression in idiopathic pulmonary
fibrosis myofibroblasts is kca3.1-dependent. Respi Res. 2014;15:155.
8. Bartram U, Speer CP. The role of transforming growth factor beta in lung
development and disease. Chest. 2004;125:754–65.
9. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide
(CNP): A new member of natriuretic peptide family identified in porcine
brain. Biochem Biophys Res Commun. 1990;168:863–70.
10. Del Ry S. C-type natriuretic peptide: A new cardiac mediator. Peptides. 2013;
40:93–8.
11. Leuranguer V, Vanhoutte PM, Verbeuren T, Feletou M. C-type natriuretic
peptide and endothelium-dependent hyperpolarization in the guinea-pig
carotid artery. Br J Pharmacol. 2008;153:57–65.
12. Del Ry S, Cabiati M, Vozzi F, Battolla B, Caselli C, Forini F, et al. Expression of
C-type natriuretic peptide and its receptor NPR-B in cardiomyocytes.
Peptides. 2011;32:1713–8.
13. Suda M, Tanaka K, Fukushima M, Natsui K, Yasoda A, Komatsu Y, et al.
C-type natriuretic peptide as an autocrine/paracrine regulator of
osteoblast. Evidence for possible presence of bone natriuretic peptide
system. Biochem Biophys Res Commun. 1996;223:1–6.
14. Totsune K, Takahashi K, Murakami O, Itoi K, Sone M, Ohneda M, et al.
Immunoreactive C-type natriuretic peptide in human adrenal glands and
adrenal tumors. Peptides. 1994;15:287–90.
15. Nielsen SJ, Gotze JP, Jensen HL, Rehfeld JF. ProCNP and CNP are expressed
primarily in male genital organs. Regul Pept. 2008;146:204–12.
16. Obata H, Yanagawa B, Tanaka K, Ohnishi S, Kataoka M, Miyahara Y, et al.
CNP infusion attenuates cardiac dysfunction and inflammation in
myocarditis. Biochem Biophys Res Commun. 2007;356:60–6.
17. Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, Mori K, et al.
C-type natriuretic peptide, a novel antifibrotic and antihypertrophic
agent, prevents cardiac remodeling after myocardial infarction. J Am Coll
Cardiol. 2005;45:608–16.
18. Bukulmez H, Khan F, Bartels CF, Murakami S, Ortiz-Lopez A, Sattar A, et al.
Protective effects of C-type natriuretic peptide on linear growth and
articular cartilage integrity in a mouse model of inflammatory arthritis.
Arthritis Rheumatol. 2014;66:78–89.
19. Peake NJ, Pavlov AM, D’Souza A, Pingguan-Murphy B, Sukhorukov GB,
Hobbs AJ, et al. Controlled release of C-type natriuretic peptide by
microencapsulation dampens proinflammatory effects induced by IL-1beta
in cartilage explants. Biomacromolecules. 2015;16:524–31.
20. Hu P, Zhang XC, Kong HB, Xia X, Hu B, Qin YH. Exogenous C-type natriuretic
peptide infusion ameliorates unilateral ureteral obstruction-induced
tubulointerstitial fibrosis in rats. Lab Invest. 2015;95:263–72.
21. Jin X, Zhang Y, Li X, Zhang J, Xu D. C-type natriuretic peptide ameliorates
ischemia/reperfusion-induced acute kidney injury by inhibiting apoptosis
and oxidative stress in rats. Life Sci. 2014;117:40–5.
22. Kuehnl A, Pelisek J, Ring A, Spindler N, Hatz R, Jauch KW, et al. C-type
natriuretic peptide slows down wound healing but promotes angiogenesis
in SKH1-hr hairless mice. Int Wound J. 2013;10:425–30.
23. Murakami S, Nagaya N, Itoh T, Fujii T, Iwase T, Hamada K, et al. C-type
natriuretic peptide attenuates bleomycin-induced pulmonary fibrosis in
mice. Am J Physiol Lung Cell Mol Physiol. 2004;287:L1172–7.
24. Kimura T, Nojiri T, Hosoda H, Ishikane S, Shintani Y, Inoue M, et al. C-type
natriuretic peptide attenuates lipopolysaccharide-induced acute lung injury
in mice. J Surg Res. 2015;194:631–7.
25. Horio T, Tokudome T, Maki T, Yoshihara F, Suga S, Nishikimi T, et al. Gene
expression, secretion, and autocrine action of C-type natriuretic peptide in
cultured adult rat cardiac fibroblasts. Endocrinology. 2003;144:2279–84.
26. Li ZQ, Liu YL, Li G, Li B, Liu Y, Li XF, et al. Inhibitory effects of C-type
natriuretic peptide on the differentiation of cardiac fibroblasts, and
secretion of monocyte chemoattractant protein-1 and plasminogen
activator inhibitor-1. Mol Med Rep. 2015;11:159–65.
27. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol
Lung Cell Mol Physiol. 2008;294:L152–60.
28. Uchida M, Shiraishi H, Ohta S, Arima K, Taniguchi K, Suzuki S, et al. Periostin,
a matricellular protein, plays a role in the induction of chemokines in
pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012;46:677–86.
Kimura et al. Respiratory Research  (2016) 17:19 Page 16 of 17
29. Agostini C, Gurrieri C. Chemokine/cytokine cocktail in idiopathic pulmonary
fibrosis. Proc Am Thorac Soc. 2006;3:357–63.
30. Akieda-Asai S, Sugiyama M, Miyazawa T, Koda S, Okano I, Senba K, et al.
Involvement of guanylin and GC-C in rat mesenteric macrophages in
resistance to a high-fat diet. J Lipid Res. 2013;54:85–96.
31. De Vooght V, Vanoirbeek JA, Haenen S, Verbeken E, Nemery B, Hoet PH.
Oropharyngeal aspiration: An alternative route for challenging in a mouse
model of chemical-induced asthma. Toxicology. 2009;259:84–9.
32. Liu F, Sun GQ, Gao HY, Li RS, Soromou LW, Chen N, et al. Angelicin regulates
LPS-induced inflammation via inhibiting MAPK/NF-kappaB pathways. J Surg
Res. 2013;185:300–9.
33. Ogino K, Zhang R, Takahashi H, Takemoto K, Kubo M, Murakami I, et al.
Allergic airway inflammation by nasal inoculation of particulate matter
(PM2.5) in NC/Nga mice. PLoS One. 2014;9:e92710.
34. Moore BB, Paine 3rd R, Christensen PJ, Moore TA, Sitterding S, Ngan R, et al.
Protection from pulmonary fibrosis in the absence of CCR2 signaling.
J Immunol. 2001;167:4368–77.
35. Becerril C, Pardo A, Montano M, Ramos C, Ramirez R, Selman M. Acidic
fibroblast growth factor induces an antifibrogenic phenotype in human
lung fibroblasts. Am J Respir Cell Mol Biol. 1999;20:1020–7.
36. Akagi T, Sasai K, Hanafusa H. Refractory nature of normal human diploid
fibroblasts with respect to oncogene-mediated transformation. Proc Natl
Acad Sci U S A. 2003;100:13567–72.
37. Miki H, Mio T, Nagai S, Hoshino Y, Nagao T, Kitaichi M, et al. Fibroblast
contractility: Usual interstitial pneumonia and nonspecific interstitial
pneumonia. Am J Respir Crit Care Med. 2000;162:2259–64.
38. Suga S, Nakao K, Kishimoto I, Hosoda K, Mukoyama M, Arai H, et al.
Phenotype-related alteration in expression of natriuretic peptide receptors
in aortic smooth muscle cells. Circ Res. 1992;71:34–9.
39. Kaneki H, Kurokawa M, Ide H. The receptor attributable to C-type natriuretic
peptide-induced differentiation of osteoblasts is switched from type B- to type
C-natriuretic peptide receptor with aging. J Cell Biochem. 2008;103:753–64.
40. Zenitani M, Nojiri T, Uehara S, Miura K, Hosoda H, Kimura T, et al. C-type
natriuretic peptide in combination with sildenafil attenuates proliferation of
rhabdomyosarcoma cells. Cancer Med. 2016 in press. doi: 10.1002/cam4.642.
41. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane
to the nucleus. Cell. 2003;113:685–700.
42. Bocchino M, Agnese S, Fagone E, Svegliati S, Grieco D, Vancheri C, et al. Reactive
oxygen species are required for maintenance and differentiation of primary lung
fibroblasts in idiopathic pulmonary fibrosis. PLoS One. 2010;5:e14003.
43. Nakanishi K, Tajima F, Itoh H, Nakata Y, Hama N, Nakagawa O, et al.
Expression of C-type natriuretic peptide during development of rat lung.
Am J Physiol. 1999;277:L996–L1002.
44. Kelley TJ, Cotton CU, Drumm ML. In vivo activation of CFTR-dependent
chloride transport in murine airway epithelium by CNP. Am J Physiol. 1997;
273:L1065–72.
45. Itoh T, Nagaya N, Murakami S, Fujii T, Iwase T, Ishibashi-Ueda H, et al. C-type
natriuretic peptide ameliorates monocrotaline-induced pulmonary
hypertension in rats. Am J Respir Crit Care Med. 2004;170:1204–11.
46. Chen G, Zhao J, Yin Y, Wang B, Liu Q, Li P, et al. C-type natriuretic peptide
attenuates LPS-induced endothelial activation: Involvement of p38, Akt, and
NF-kappaB pathways. Amino Acids. 2014;46:2653–63.
47. Gauldie J. Pro: Inflammatory mechanisms are a minor component of the
pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.
2002;165:1205–6.
48. Tilman G, Mattiussi M, Brasseur F, van Baren N, Decottignies A. Human periostin
gene expression in normal tissues, tumors and melanoma: Evidences for
periostin production by both stromal and melanoma cells. Mol Cancer. 2007;6:80.
49. Jackson-Boeters L, Wen W, Hamilton DW. Periostin localizes to cells in
normal skin, but is associated with the extracellular matrix during wound
repair. J Cell Commun Signal. 2009;3:125–33.
50. Oka T, Xu J, Kaiser RA, Melendez J, Hambleton M, Sargent MA, et al. Genetic
manipulation of periostin expression reveals a role in cardiac hypertrophy
and ventricular remodeling. Circ Res. 2007;101:313–21.
51. Yang L, Serada S, Fujimoto M, Terao M, Kotobuki Y, Kitaba S, et al. Periostin
facilitates skin sclerosis via PI3K/Akt dependent mechanism in a mouse
model of scleroderma. PLoS One. 2012;7:e41994.
52. Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, et al.
Periostin promotes fibrosis and predicts progression in patients with
idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012;303:
L1046–56.
53. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The
myofibroblast: One function, multiple origins. Am J Pathol. 2007;170:1807–16.
54. Phan SH. Fibroblast phenotypes in pulmonary fibrosis. Am J Respir Cell Mol
Biol. 2003;29:S87–92.
55. Li M, Krishnaveni MS, Li C, Zhou B, Xing Y, Banfalvi A, et al. Epithelium-
specific deletion of TGF-beta receptor type II protects mice from bleomycin-
induced pulmonary fibrosis. J Clin Invest. 2011;121:277–87.
56. Klingberg F, Chow ML, Koehler A, Boo S, Buscemi L, Quinn TM, et al.
Prestress in the extracellular matrix sensitizes latent TGF-beta1 for activation.
J Cell Biol. 2014;207:283–97.
57. Petrov VV, Fagard RH, Lijnen PJ. Stimulation of collagen production by
transforming growth factor-beta1 during differentiation of cardiac
fibroblasts to myofibroblasts. Hypertension. 2002;39:258–63.
58. Kapoun AM, Liang F, O’Young G, Damm DL, Quon D, White RT, et al. B-type
natriuretic peptide exerts broad functional opposition to transforming growth
factor-beta in primary human cardiac fibroblasts: Fibrosis, myofibroblast
conversion, proliferation, and inflammation. Circ Res. 2004;94:453–61.
59. Li P, Wang D, Lucas J, Oparil S, Xing D, Cao X, et al. Atrial natriuretic peptide
inhibits transforming growth factor beta-induced smad signaling and
myofibroblast transformation in mouse cardiac fibroblasts. Circ Res. 2008;
102:185–92.
60. Krejci P, Masri B, Fontaine V, Mekikian PB, Weis M, Prats H, et al. Interaction
of fibroblast growth factor and C-natriuretic peptide signaling in regulation
of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci.
2005;118:5089–100.
61. Nojiri T, Hosoda H, Tokudome T, Miura K, Ishikane S, Kimura T, et al. Atrial
natriuretic peptide inhibits lipopolysaccharide-induced acute lung injury.
Pulm Pharmacol Ther. 2014;29:24–30.
62. Nojiri T, Hosoda H, Tokudome T, Miura K, Ishikane S, Otani K, et al. Atrial
natriuretic peptide prevents cancer metastasis through vascular endothelial
cells. Proc Natl Acad Sci U S A. 2015;112:4086–91.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kimura et al. Respiratory Research  (2016) 17:19 Page 17 of 17
